ACCCBUZZ BLOG

ACCCBuzz shares highlights from the NCCN Policy Summit: Reducing the Cancer Burden through Prevention and Early Detection, highlighting the real impacts felt by patients and providers in cancer risk identification and reduction.

State legislation across the U.S. is tackling health insurance coverage for comprehensive biomarker testing. Learn more about what's going on where you live and across the nation.

ACCCBuzz spoke with Dr. Dan Vogl to learn more about the treatment options available to patients with multiple myeloma, including the benefits of adding anti-CD38 monoclonal antibodies in either first- or second-line treatment.

Care optimization is everything in today’s rapidly changing healthcare landscape. Learn how ACCC's nationwide quality improvement (QI) initiative helped Southern Ohio Medical Center Cancer Center develop and implement plans to support the optimization of care for patients diagnosed with Stages III and IV non-small cell lung cancer (NSCLC).

On September 16, the National Comprehensive Cancer Network convened experts and stakeholders in D.C. for a policy summit spotlighting today’s cancer screening and prevention landscape. Learn what speakers discussed, including what changes need to happen to create an equitable future for all people at risk—or not—for cancer.

Learn how ACCC's bispecific antibody initiative “Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management”—developed in partnership with the Society for Immunotherapy of Cancer—will help expand the use of these novel therapies and optimize care for patients with cancer.

Communities around the globe recognize August 1 as World Lung Cancer Day—a day to commemorate, educate, and support individuals and families impacted by lung cancer. Read highlights on a few ACCC initiatives that are helping cancer care teams better support their patients with this disease.

To fill a care gap, The James Cancer Hospital opened a new set of front doors to its facility—The James Cancer Diagnostic Center—to ensure all patients with a concern for cancer could be quickly evaluated, even if they didn’t have a confirmed diagnosis.

Measurable residual disease (MRD) has gained traction as a compelling marker for disease status across various hematologic malignancies, including multiple myeloma. Learn how MRD is uniquely suited to help evaluate the depth of treatment response.

With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.

Advocating on behalf of their patients and programs, ACCC members from 14 states participated in Virtual Hill Day, speaking with Congress and their staff on key legislation asks regarding access to care, telehealth, prior authorizations, and more.

In recognizing Cancer Immunotherapy Month and National Cancer Survivors Day (June 5), ACCC is highlighting the resources it has created to assist the multidisciplinary team in creating and adapting survivorship care plans to meet these patients’ unique needs and support toxicity management for better outcomes.

Testing for measurable residual disease can shape treatment choices and patient management to achieve better outcomes, and the need persists for members of the multidisciplinary cancer care team to better understand the purpose, use, and significance of this testing in all cancer treatment settings.

Carolina Blood and Cancer Care Associate's No One Left Alone (or NOLA) initiative is a multi-phase pilot program aimed at lessening disparities in cancer care in three key areas: care access, biomarker testing, and clinical trials.

March is Multiple Myeloma Awareness Month. Learn how ACCC is supporting collaboration among healthcare providers with practical, scalable solutions to the real-world challenges of improving quality care delivery for patients with multiple myeloma.

While precision medicine in cancer care is becoming more widespread, its rapid evolution in oncology requires ongoing discussion. ACCC’s podcast, CANCER BUZZ, features lively expert discussions about emergent issues in cancer care. Here we highlight some of those podcasts.

ACCC has launched Transforming Complex to Clear—a precision medicine campaign that has developed a range of tools and resources to help bring clarity to complex patient care decisions. Designed for multidisciplinary cancer teams, learn more about how these resources can enable clinicians to make educated and confident decisions.

In launching its new campaign, Transforming Complex To Clear, ACCC brought together expert panelists to discuss effective practices and offer tips to address current barriers to biomarker testing in the community setting.

Liquid biopsy, a genetic test that can eliminate some of the most serious potential drawbacks of traditional tissue biopsy, is gaining more traction in cancer care. But there remain significant barriers to its widespread use.

To help address the ongoing prevalence of colorectal cancer, ACCC is inviting its members to submit proposals for quality improvement initiatives in treating metastatic forms of this cancer.

Led by the Prevent Cancer Foundation, ACCC has joined more than 300 organizations in signing a letter urging the passage of the MCED Screening Coverage Act, which will help cancer care providers be able to use the latest testing technologies to improve quality of life and better patient outcomes.

Montana is one of the most rural states in the U.S., with nearly half of its population living in rural regions. Accordingly, accessing healthcare services can be difficult for Montana’s citizens, and gaining access to clinical trials is particularly challenging.

Recent advances in immuno-oncology (IO) therapies have led to rapid, effective treatments for subsets of patients with cancers that have proven resistant to conventional treatments.

Growing knowledge of NSCLC subtypes and molecular biomarkers for this disease has led to changes in how NSCLC is diagnosed and staged.

In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.